Therapy visit-limit denial: when a session cap is a parity problem

Denials of outpatient psychotherapy after a visit cap — or after a medical-necessity review of “too many” sessions — can raise a parity issue: a quantitative or nonquantitative limit applied to mental-health visits that the plan doesn't apply to comparable medical/surgical visits. The appeal pairs the clinical case for continued treatment with a parity challenge to the limit itself.

How therapy visit limit is covered

Routine outpatient therapy is covered on medical necessity, but plans sometimes apply visit caps or trigger medical-necessity review after a number of sessions. Under MHPAEA, a hard visit cap on mental-health therapy that has no comparable counterpart on medical/surgical care, or a medical-necessity rule applied more stringently to therapy, can be impermissible. On request, the plan must produce its NQTL comparative analysis.

Why therapy visit limit claims get denied

• A fixed visit/session cap was reached.
• Medical-necessity review triggered after a threshold number of sessions.
• Prior authorization required for continued therapy and missing.
• Out-of-network provider.
• The limit has no comparable medical/surgical counterpart — a potential parity violation.

Is a therapy visit limit denial worth appealing?

How to appeal a therapy visit limit denial

1. 1

   Make the clinical case for continuation

   Document the diagnosis, the response to ongoing therapy, and the clinical risk of interrupting it before goals are met.

2. 2

   Raise parity on the limit itself

   Ask whether comparable medical/surgical visits face the same cap or review. If not, challenge the limit under parity and request the NQTL comparative analysis.

3. 3

   Escalate to external review

   If the internal appeal fails, an external review can address both the medical-necessity and parity questions; ERISA governs self-funded plans.

therapy visit limit — frequently asked

FDA-approved indications and payer prior-authorization criteria are paraphrased for plain-language reference, not reproduced verbatim, and vary by plan. This is general information, not medical, legal, or coverage advice — confirm against the current FDA label, the plan's policy, and the patient's benefit documents.